Lucerastat
Tier C — Watch / tradeLucerastat
Targets：UGCG
Indications (approved)：Fabry disease
Regional status
Synthetic routes & intermediates1 routes
Routes are ordered originator first, then optimised / process (non-patent) routes; each lists steps, overall yield and the intermediate table (code / CAS / name) — ready for supplier sourcing and RFQ. Rendered by this site from structured data; no third-party route graphics used.
| Code | CAS No. | Intermediate |
|---|---|---|
| LUCER-001 | - | (2R,3S,4R,5S)-2-(hydroxymethyl)piperidine-3,4,5-triol |
| LUCER-002 | 123-72-8 | butyraldehyde |
| Lucerastat | 141206-42-0 | - |
Frequently asked questions
What are the approved indications of Lucerastat?
Approved indications include: Fabry disease.
When does the Lucerastat patent expire?
No public expiry year is available for Lucerastat yet; this page updates once verified.
How many synthesis routes are recorded for Lucerastat?
1 synthesis routes are recorded; the shortest is 1 steps with / total yield. Intermediates in each route carry codes and CAS numbers.
Where can I buy Lucerastat intermediates?
All intermediates in Lucerastat routes have CAS profiles — you can submit an RFQ per CAS and it enters the Unibest matching pool.
How do I get a quote for Lucerastat intermediates?
Open the CAS profile of the target intermediate from this page, or submit an RFQ directly — the CAS enters the matching flow automatically and the supply network responds with quotes.
Source: cross-verified data (structured fields only) · 2026-10-08